🏛️ The Patent vs. Public Health Dilemma

🌟 Imagine a life-saving cancer drug exists, it's patented, but costs ₹2.8 lakh per month while a generic version could cost just ₹8,800. When should an inventor's 20-year monopoly give way to public need?

💡 What You'll Discover:

• 🔍 Why patents last exactly 20 years from application date - and when that changes
• ⚖️ How compulsory licensing under Section 84 can break patent monopolies after 3 years
• 🎯 The difference between patents and copyrights - and why patents are more powerful
• 💊 When public health trumps private profits in Indian law

🚀 Real Cases Discussed:

• 💎 Bayer Corporation vs. Union of India (2014) - The landmark case where a cancer drug's ₹2.8 lakh monthly cost was challenged
• ⭐ Natco Pharma's compulsory license application - How an Indian company broke Bayer's monopoly on Sorafenib Tosylate (Nexavar)

🎭 The Three-Way Balance:

• 🏭 Rewarding innovation through temporary monopolies
• 🤝 Ensuring public access to essential medicines
• 🇮🇳 Promoting local manufacturing over mere imports

🎙️ This episode reveals how Indian courts balance billion-dollar R&D investments against life-and-death access to medicines - a legal tightrope walk that affects millions!